RLS 1496
Alternative Names: RLS-1496Latest Information Update: 24 Apr 2024
At a glance
- Originator Rubedo Life Sciences
- Class Anti-inflammatories; Antipsoriatics; Skin disorder therapies; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Atopic dermatitis; Psoriasis
- Research Scleroderma
Most Recent Events
- 23 Apr 2024 Rubedo Life Sciences plans to initiate a phase I trial
- 03 Jan 2024 Early research in Scleroderma in USA (unspecified route), prior to January 2024 (Rubedo Life Sciences pipeline, January 2024)
- 03 May 2023 Rubedo Life Sciences plans first-in-human studies trial for Atopic dermatitis and psoriasis in 2024 (Unspecified route)